News & Events
2022-10-17
Dr. Yoshihiro Kawano joins SYNCELL as Senior Director of Engineering

TAIPEI, Taiwan – October 17, 2022 -- SYNCELL, a spatial biology system company, today announced that Dr. Yoshihiro Kawano, Ph.D., has joined SYNCELL as senior director of engineering. As part of his role, he will be responsible for the Microscoop instrument production.

SYNCELL’S Microscoop™ spatial proteomics system uses AI to guide the image recognition and photolabeling of target of interest and is the only spatial proteomics system that utilizes the optoproteomics technology to label proteins in a specific cell type or subcellular structure in fixed cells or tissue samples.

Dr. Kawano brings to SYNCELL 35 years of biomedical industry experience with a broad expertise in engineering, marketing strategies, and business development. Before joining SYNCELL, he held senior management positions at Olympus Corporation and Konica Minolta REALM in Japan.

“We’re pleased to welcome Dr. Kawano to SYNCELL,” said Jung-Chi Liao, Ph.D., founder and CEO of SYNCELL. “While at Olympus Corporation and Olympus America, he distinguished himself as a strategic leader and product innovator who at the same time understands both the business and clinical sides of taking new technologies to market. Dr. Kawano will be instrumental in leading the production and growth of Microscoop as we roll out system access to researchers globally.”

“I’m excited to join SYNCELL,” said Dr. Yoshihiro Kawano, Ph.D., senior director of engineering for SYNCELL. “Microscoop’s technology is well positioned to have a huge impact on biomedical research. This, together with SYNCELL’s strong leadership and product development team, made it an easy decision. “Microscoop will soon empower data discovery to enable advancements in therapeutic treatments previously not possible and I’m looking forward to helping bring this important advancement to market. “

Before moving into business planning and marketing, Dr. Kawano had a 20-year stellar engineering and product development career at Olympus Corporation. He had more than 30 inventions and received the Olympus President's Award in 1995 for “The Development of a Research Inverted System Microscope.” A certified project management professional (PMP), he was the project leader for developing new scientific equipment, such as a phase contrast microscope, an inverted microscope, a whole-mouse imaging system and consumables. He received a Bachelor of Arts degree in engineering from Tokai University, where he studied electro-photo-optics and completed his Ph.D. in biomedical engineering at Tohoku University in Japan. He has also received an MBA from Bond University in Australia.

About SYNCELL Inc.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

2022-10-17
Dr. Yoshihiro Kawano joins SYNCELL as Senior Director of Engineering

TAIPEI, Taiwan – October 17, 2022 -- SYNCELL, a spatial biology system company, today announced that Dr. Yoshihiro Kawano, Ph.D., has joined SYNCELL as senior director of engineering. As part of his role, he will be responsible for the Microscoop instrument production.

SYNCELL’S Microscoop™ spatial proteomics system uses AI to guide the image recognition and photolabeling of target of interest and is the only spatial proteomics system that utilizes the optoproteomics technology to label proteins in a specific cell type or subcellular structure in fixed cells or tissue samples.

Dr. Kawano brings to SYNCELL 35 years of biomedical industry experience with a broad expertise in engineering, marketing strategies, and business development. Before joining SYNCELL, he held senior management positions at Olympus Corporation and Konica Minolta REALM in Japan.

“We’re pleased to welcome Dr. Kawano to SYNCELL,” said Jung-Chi Liao, Ph.D., founder and CEO of SYNCELL. “While at Olympus Corporation and Olympus America, he distinguished himself as a strategic leader and product innovator who at the same time understands both the business and clinical sides of taking new technologies to market. Dr. Kawano will be instrumental in leading the production and growth of Microscoop as we roll out system access to researchers globally.”

“I’m excited to join SYNCELL,” said Dr. Yoshihiro Kawano, Ph.D., senior director of engineering for SYNCELL. “Microscoop’s technology is well positioned to have a huge impact on biomedical research. This, together with SYNCELL’s strong leadership and product development team, made it an easy decision. “Microscoop will soon empower data discovery to enable advancements in therapeutic treatments previously not possible and I’m looking forward to helping bring this important advancement to market. “

Before moving into business planning and marketing, Dr. Kawano had a 20-year stellar engineering and product development career at Olympus Corporation. He had more than 30 inventions and received the Olympus President's Award in 1995 for “The Development of a Research Inverted System Microscope.” A certified project management professional (PMP), he was the project leader for developing new scientific equipment, such as a phase contrast microscope, an inverted microscope, a whole-mouse imaging system and consumables. He received a Bachelor of Arts degree in engineering from Tokai University, where he studied electro-photo-optics and completed his Ph.D. in biomedical engineering at Tohoku University in Japan. He has also received an MBA from Bond University in Australia.

About SYNCELL Inc.
SYNCELL is a development stage company with a vision to revolutionize in situ cell biology and biomedical research. The company will soon introduce its groundbreaking Microscoop™ platform, the first and only system that allows users to pick up, identify and quantify thousands of known and unknown proteins in specified cellular and subcellular locations. Microscoop™ is pairing unique imaging and illuminating capabilities with novel photolabeling chemicals to provide deep spatial proteomics insights to transform a wide range of basic biology and translational research including neuroscience, oncology, immunology, infectious disease, gene therapy, and to identify novel therapeutic targets with spatial context to accelerate drug discovery and development programs.

This website stores cookies on your computer.
 We use cookies to personalise content and ads, to provide social media features and to analyse our traffic. We also share information about your use of our site with our social media, advertising and analytics partners who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Accept